Drugs / Tetrandrine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 43 trials | ||||||
| Phase 4 | NCT05697029 | Dec 2023 → Dec 2025 | COVID-19 | Peking University Third Hospital | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT07319598 | Nov 2023 → Oct 2026 expected | interstitial lung disease | Peking University Third Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04308317 | Mar 2020 → Mar 2021 | COVID-19 | Henan Provincial People's Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05245448 | Feb 2022 → Oct 2023 | rheumatoid arthritis | Peking University People's Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetrandrine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05245448 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Tetrandrine is a traditional Chinese medicine.” NCT04308317 ↗ |
| Route | Oral | “Administered orally” NCT05245448 ↗ |